EP0871480A4 - T-LYMPHOCYTES TRIGGERING AN IMMUNE REACTION AND METHODS OF USE - Google Patents

T-LYMPHOCYTES TRIGGERING AN IMMUNE REACTION AND METHODS OF USE

Info

Publication number
EP0871480A4
EP0871480A4 EP97912648A EP97912648A EP0871480A4 EP 0871480 A4 EP0871480 A4 EP 0871480A4 EP 97912648 A EP97912648 A EP 97912648A EP 97912648 A EP97912648 A EP 97912648A EP 0871480 A4 EP0871480 A4 EP 0871480A4
Authority
EP
European Patent Office
Prior art keywords
lymphocytes
triggering
methods
immune reaction
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97912648A
Other languages
German (de)
French (fr)
Other versions
EP0871480A1 (en
Inventor
David Berd
Giorgio Parmiani
Andrea Anichini
Marialuisa Sensi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of EP0871480A1 publication Critical patent/EP0871480A1/en
Publication of EP0871480A4 publication Critical patent/EP0871480A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP97912648A 1996-10-04 1997-10-02 T-LYMPHOCYTES TRIGGERING AN IMMUNE REACTION AND METHODS OF USE Withdrawn EP0871480A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2700296P 1996-10-04 1996-10-04
PCT/US1997/015741 WO1998014206A1 (en) 1996-10-04 1997-10-02 T cells mediating an immune response and methods of use
US27002P 2008-02-07

Publications (2)

Publication Number Publication Date
EP0871480A1 EP0871480A1 (en) 1998-10-21
EP0871480A4 true EP0871480A4 (en) 2001-04-04

Family

ID=21835095

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97912648A Withdrawn EP0871480A4 (en) 1996-10-04 1997-10-02 T-LYMPHOCYTES TRIGGERING AN IMMUNE REACTION AND METHODS OF USE

Country Status (7)

Country Link
EP (1) EP0871480A4 (en)
AU (1) AU4976697A (en)
CA (1) CA2242590A1 (en)
IL (1) IL125747A0 (en)
NZ (1) NZ330995A (en)
PL (1) PL328790A1 (en)
WO (1) WO1998014206A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301174A (en) * 1998-04-09 2001-06-27 托马斯杰斐逊大学 Method of inducing an anti-tumor response against a lung metastasis in a melanoma patient
AU3786999A (en) * 1998-05-04 1999-11-23 Thomas Jefferson University Composition comprising tumor cells and extracts and method of using thereof
DE60031100T2 (en) 1999-03-16 2007-03-08 Thomas Jefferson University HAPTEN MODIFIED TUMOR CELLS AND METHOD OF PREPARATION AND THEIR USE
US7297330B2 (en) * 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy
EP1551225A4 (en) 2002-06-10 2011-05-25 Avax Technologies Inc CRYO-PRESERVATION OF HUMAN TUMOR CELLS
US20070134670A1 (en) * 2003-12-12 2007-06-14 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN-BINDING CONSTRUCTS AND GENERALLY MODIFIED T-CELLS FOR THE TREATMENT OF DISEASES
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB2595980B (en) * 2019-01-04 2023-06-14 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (en) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Multifunctional molecules that bind to T-cell-associated cancer cells and uses thereof
CN116234829A (en) 2020-01-03 2023-06-06 马伦戈治疗公司 Anti-TCR antibody molecules and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0668350A1 (en) * 1994-02-16 1995-08-23 Akzo Nobel N.V. Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806565A1 (en) * 1988-03-01 1989-09-14 Deutsches Krebsforsch VIRUS-MODIFIED TUMOR VACCINES FOR THE IMMUNOTHERAPY OF TUMOR METAL KEYS
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
KR19990022592A (en) * 1995-06-07 1999-03-25 아브람 엠. 골드핑거 Tumor cell extracts modified with hapten and methods for treating or screening cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0668350A1 (en) * 1994-02-16 1995-08-23 Akzo Nobel N.V. Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAIGNARD A ET AL: "In situ demonstration of renal-cell-carcinoma-specific T-cell clones.", INTERNATIONAL JOURNAL OF CANCER, vol. 66, no. 4, 1996, pages 564 - 570, XP002159122 *
SATO T: "Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine.", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 43, no. 3, 1996, pages 174 - 179, XP000953008 *
See also references of WO9814206A1 *
SENSI M ET AL.: "Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.", JOURNAL OF CLINICAL INVESTIGATION, vol. 99, no. 4, 15 February 1997 (1997-02-15), pages 710 - 717, XP000953042 *
SENSI M ET AL.: "Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 92, no. 12, 1 June 1995 (1995-06-01), pages 5674 - 5678, XP002143225 *
WEIDMANN E ET AL.: "Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.", CANCER RESEARCH, vol. 53, no. 20, 1993, pages 4745 - 4749, XP002150949 *

Also Published As

Publication number Publication date
EP0871480A1 (en) 1998-10-21
AU4976697A (en) 1998-04-24
CA2242590A1 (en) 1998-04-09
IL125747A0 (en) 1999-04-11
NZ330995A (en) 2000-12-22
PL328790A1 (en) 1999-02-15
WO1998014206A1 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
EP1018987A4 (en) NEOCARTILAGE AND ITS METHODS OF USE
PL329930A1 (en) Antigens of human lymphocytes b and related reagents
ID21085A (en) ASSOCIATION AND FIELD OF SEPARATION FOR ELECTRICAL USE OF PERSONAL USE COMMUNICATION.
IT1290006B1 (en) ALCHYLPHENYLBISACYLPHOSPHYNOXES AND MIXTURES OF PHOTOS INITIATORS
NZ329462A (en) Stilbene derivatives containing an adamantyl group and medicaments thereof
MA21131A1 (en) COPOLYMERS OF TEREPHTHALATE ESTERS AND THEIR USE IN WHITENING COMPOSITIONS.
DK0634216T3 (en) Agglutination reaction and separation vessel
ID19769A (en) SYNTHESIS OF CHEMICAL AND ISOPRENOID USES
EP0871480A4 (en) T-LYMPHOCYTES TRIGGERING AN IMMUNE REACTION AND METHODS OF USE
MA24273A1 (en) (4-ARYLTHIAZOL-2YL) SULFONAMIDES AND THEIR USE
ID22672A (en) PLATE AND PLATE RECORDING EQUIPMENT
ID18456A (en) PRODUCTION-JOINT 6-AMINOCAPRONITRIL AND HEXSAMETYLENADIAMINA
GB2267973B (en) Metallic block for detecting force operating on metallic V-belt and system for detection of operating force using the same
AU2929689A (en) Idiotype and anti-idiotype antibodies useful in virus detection
MA23794A1 (en) USE OF PHENYLCYCLOHEXYLCARBOXAMIDES
IT1298175B1 (en) IMPROVED PROCEDURE FOR THE POLYMERIZATION AND COPOLYMERIZATION OF OLEFINE
DE69803245D1 (en) Imaging device and determination of the connected device
ZA939756B (en) Monocional antibodies and anti-idiotypic antibodies to hepatitits c virus
KR970706592A (en) INTEGRATING ACCELEROMETER CAPABLE OF SENSING OFF-AXIS INPUTS
ID18913A (en) DECLARATION OF ITENOPIRIDINE AND ITS USE
DE69826947D1 (en) Force and motion converter
DE69318047D1 (en) Very fast sample and hold signal generator
FR2729524B1 (en) SUPPRESSION CIRCUIT AND ACCENTATION CIRCUIT
ATA116593A (en) SEPARATING AND SPLITTING DEVICE
KR940027054U (en) Combined structure of motor set and motor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 980714;LT PAYMENT 980714;LV PAYMENT 980714;RO PAYMENT 980714;SI PAYMENT 980714

17P Request for examination filed

Effective date: 19981001

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 5/06 A, 7G 01N 33/574 B, 7C 07K 14/705 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010215

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20010615